Lugano, Switzerland, 25 June 2025 – The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies. The Congress will cover a broad spectrum of topics – from molecular prevention and precision therapy to patient-centred approaches and quality of life. Congress sessions will be held onsite and will also be live streamed via the Virtual Congress Platform.
Programme picks
New data on the efficacy, safety, and impact on patients’ quality of life of a combined immunotherapy in the treatment of hepatocellular carcinoma and colorectal cancer.
Related content: LBA3 , 1O , 148O
Findings on the use of ctDNA in colorectal cancer care, including liquid biopsy-guided selection of patients for anti-EGFR re-treatment.
Related content: 2O , 3O , 4O, 6MO , 15P , 16P , 17P , 19P , 42P
Results on overall survival for gastric cancer patients with CDH1 pathogenic variant undergoing surveillance.
Related content: 393MO
Insights on specificities and challenges of early-onset colorectal cancer (EOCRC): from molecular footprint and clinical features to potential biomarkers for early detection and the need for earlier screening.
Related content: 70P, 77P, 79P, 80P, 82P , Special Symposium
Keynote Sessions
“Molecular biology insights in pancreatic cancer" , by Anirban Maitra and
“Epidemiology: Trends and causes of gastrointestinal cancers” by Elisabete Weiderpass 2 July, 13:00 - 14:00 CEST
“Decoding genome and transcriptome signatures in colorectal cancer” , by Federica Di Nicolantonio, 3 July, 10:00 - 10:30 CEST
“Blood tests for colorectal cancer screening and more wide cancer screening” by Frank A. Sinicrope, 4 July, 10:00 - 10:30 CEST
The abstracts will be published online as a supplement to Annals of Oncology . The abstract titles can be viewed through the online programme .
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for ESMO Gastrointestinal Cancers Congress 2025. To apply for press accreditation, please fill out the form available here . Please be kindly informed that onsite press accreditation will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org ).
Further information
ESMO Press Office
press@esmo.org
Notes to editors
Please make sure to use the official name of the meeting in your reports: ESMO Gastrointestinal Cancers Congress 2025 and the official congress hashtag #ESMOGI25. Follow it to stay up to date and use it to take part in the conversation on X , LinkedIn, Bluesky , Instagram, Facebook, YouTube .
About the European Society for Medical Oncology (ESMO)
Representing more than 40,000 oncology professionals from 179 countries and territories, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org